Prodrug of tenofovir diphosphate approved for combination HIV therapy

January 2002
American Journal of Health-System Pharmacy;1/1/2002, Vol. 59 Issue 1, p18
Academic Journal
Reports on United States Food and Drug Administration's market approval of tenofovir disopropxil fumarate for the treatment of HIV. Drug effectiveness; Findings of clinical trials; Drug bioavailability; Dosage recommendation; Adverse effects of the drug.


Related Articles

  • Emtriva Receives FDA Nod.  // Guide;Nov2003, Vol. 23 Issue 11, p46 

    Reports on the U.S. Food and Drug Administration's approval of Emtriva for use in combination with other antiretroviral agents in the treatment of HIV infection. Assessment of nucleoside reverse transcriptase inhibitor Emtriva by genotypic or phenotypic testing; Increase in mean baseline CD4...

  • FDA Approves Viread for HIV-1 Infection.  // FDA Consumer;Jan/Feb2002, Vol. 36 Issue 1, p5 

    Reports that the United States Food and Drug Administration has approved Viread, an antiviral drug for the treatment of HIV-1 infection in combination with other antiretroviral medicines. Most frequently reported adverse events among patients in the clinical trials; Marketer of Viread.

  • US Okays More Potent HIV Drug Formulation.  // Clinical Infectious Diseases;2/15/2005, Vol. 40 Issue 4, preceding p1 

    This article reports that the U.S. Food and Drug Administration has granted approval to a more potent formulation of Roche AG's HIV drug invirase, meaning that patients will not need to take as many of the pills.

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Dec2008, Vol. 22 Issue 12, p1021 

    The article offers news briefs related to HIV antiviral agents in the U.S. The World Health Organization (WHO) advises doctors to start early the treatment of HIV-infected babies to eliminate the bad effects of the treatment. Quest Clinical researchers reveal that etravirine does not contain...

  • Hepatitis C in HIV-Infected Patients: Impact of Direct-Acting Antivirals. Bichoupan, Kian; Dieterich, Douglas // Drugs;Jun2014, Vol. 74 Issue 9, p951 

    Approximately 30 % of HIV-infected patients are co-infected with hepatitis C virus (HCV). After the release of highly active antiretroviral therapy, liver disease has become the leading cause of morbidity and mortality in HIV patients. Prior to 2011, HCV treatment with pegylated-interferon and...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Feb2011, Vol. 25 Issue 2, p123 

    No abstract available.

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Aug2010, Vol. 24 Issue 8, p527 

    The article offers news briefs related to antiviral agents. Findings of a study conducted at the University of Alabama at Birmingham show that only 51% of HIV-exposed infants in some African countries receive the prevention drug nevirapine. Three human antibodies that neutralize HIV were...

  • Generic abacavir sulfate tablets approved.  // AIDS Alert;Aug2010, Vol. 25 Issue 8, p96 

    The article reports on the tentative approval of a generic formulation of abacavir sulfate tablets by the U.S. Food and Drug Administration (FDA).

  • Etravirine: An NNRTI for resistant HIV-1 infection. Tanzi, Maria G. // Pharmacy Today;Mar2008, Vol. 14 Issue 3, p25 

    The article focuses on the etravirine tablets, the first non-nucleoside reverse transcriptase inhibitor (NNRTI) used in treating patients with HIV-resistant to an NNRTI in the U.S. The approval of etravirine by the Food and Drug Administration (FDA) offers an additional choice for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics